Houtan Noushmehr, Ph.D.
Affiliations: | 2011 | Genetic, Molecular, and Cell Biology | University of Southern California, Los Angeles, CA, United States |
Area:
Bioinformatics Biology, Genetics, Medicine and SurgeryGoogle:
"Houtan Noushmehr"Parents
Sign in to add mentor| Peter W. Laird | grad student | 2011 | USC | |
| (Integrated genomic & epigenomic analyses of glioblastoma multiforme: Methods development and application.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Malta TM, Sabedot TS, Morosini NS, et al. (2023) The epigenetic evolution of glioma is determined by the IDH1 mutation status and treatment regimen. Cancer Research |
| Gielniewski B, Poleszak K, Roura AJ, et al. (2023) Targeted sequencing of cancer-related genes reveals a recurrent TOP2A variant which affects DNA binding and coincides with global transcriptional changes in glioblastoma. International Journal of Cancer |
| Varn FS, Johnson KC, Martinek J, et al. (2022) Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell |
| Herrgott GA, Asmaro KP, Wells M, et al. (2022) Detection of Tumor-specific DNA Methylation Markers in the Blood of Patients with Pituitary Neuroendocrine Tumors. Neuro-Oncology |
| Mosella MS, Sabedot TS, Silva TC, et al. (2021) DNA Methylation-based Signatures Classify Sporadic Pituitary Tumors According to Clinicopathological Features. Neuro-Oncology |
| Sabedot T, Malta T, Snyder J, et al. (2021) A serum-based DNA methylation assay provides accurate detection of glioma. Neuro-Oncology |
| Chen J, Mitra A, Li S, et al. (2020) Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGF-β Signaling. Cancer Research |
| Colaprico A, Olsen C, Bailey MH, et al. (2020) Interpreting pathways to discover cancer driver genes with Moonlight. Nature Communications. 11: 69 |
| Wells M, Asmaro KP, Sabedot TS, et al. (2020) OR32-03 Serum Cell-Free Methylation-Based Signatures Distinguishes Pituitary Tumors According to Functional Status and from Other Neoplasia: A Liquid Biopsy Approach Journal of the Endocrine Society. 4 |
| Wells M, Asmaro K, Rock J, et al. (2020) Abstract A11: Serum cell-free DNA methylome-based signatures distinguish pituitary tumor from other neoplasias and by clinicopathologic features Clinical Cancer Research. 26 |